Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

Published Date: 16 Aug 2023

First-line atezolizumab monotherapy is linked to improved overall survival compared to single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

The pandemic had little impact on mental health symptoms.

4.

FDA Approves New Bladder Cancer First-Line Standard of Care.

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot